CORDIS
EU research results

CORDIS

English EN
Driving next generation autophagy researchers towards translation

Driving next generation autophagy researchers towards translation

Objective

The manipulation of autophagy has an enormous therapeutic potential to revolutionize the way we currently treat cancers, neurodegenerative disorders, inflammatory and infectious diseases. Despite the great promises made by pioneering medical studies, the still limited applied research on autophagy has hampered the translation of fundamental knowledge into clinical-grade products and improved healthcare. Applied autophagy research is essential to understand the roles of autophagy in the different physiological and pathological situations, to generate (disease) models and develop biomarkers and assays to assess its progress.

The goal of the ETN Driving next generation autophagy researchers towards translation (DRIVE) is to train young scientists to fill this gap. DRIVE will equip its ESRs with an unique combination of knowledge and experimental expertise that are brought together in this consortium by the different partners. The realization of their projects in applied autophagy research will benefit of an exceptional interdisciplinary platform integrating cell biology, biochemistry, molecular biology, genetics, chemistry and “omics” approaches. In addition, DRIVE ESRs will acquire competencies to exploit the results for the development of products and techniques of commercial value. These ESRs will also be trained in disseminating results and knowledge through modern channels of communication.

Coordinator

ACADEMISCH ZIEKENHUIS GRONINGEN

Address

Hanzeplein 1
9713 Gz Groningen

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 510 748,56

Participants (14)

Sort alphabetically

Sort by EU Contribution

Expand all

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 262 875,60

HELSINGIN YLIOPISTO

Finland

WEIZMANN INSTITUTE OF SCIENCE

Israel

EU Contribution

€ 260 300,52

UNIVERSITETET I OSLO

Norway

EU Contribution

€ 286 275,24

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

EU Contribution

€ 495 745,92

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 249 216,48

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

United Kingdom

EU Contribution

€ 273 287,88

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 273 287,88

ANAXOMICS BIOTECH, S.L.

Spain

EU Contribution

€ 247 872,96

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany

EU Contribution

€ 249 216,48

ADJUVATIS

France

EU Contribution

€ 262 875,60

QPS NETHERLANDS BV

Netherlands

UNIVERSITAETSKLINIKUM FREIBURG

Germany

EU Contribution

€ 249 216,48

TURUN YLIOPISTO

Finland

EU Contribution

€ 269 145,36

Partners (20)

Sort alphabetically

Expand all

ENYO PHARMA

Sprint Bioscience AB

Pfizer

Takeda Millennium

e.mersion studio

University of Michigan/Autophagy Journal

Elsevier

COST action Transautophagy

Club Francophone de l'Autophagie

Nordic Autophagy Network

Network of Excellence for Autophagy Research

GBM Studiengruppe Autophagy

Stichting Healthy Ageing Network Northern Netherlands

Wenckebach Institute

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

Technology and Transfer Office

The Edmond & Lily Safra Children's Hospital, Sheba Medical Centre

Universitat Pompeu Fabra

RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

Project information

Grant agreement ID: 765912

Status

Ongoing project

  • Start date

    1 November 2017

  • End date

    31 October 2021

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 890 064,96

  • EU contribution

    € 3 890 064,96

Coordinated by:

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands